1276284

Ajanta Pharma USA Inc — FEI 3010721419

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
July 22, 2025
Fiscal Year
2025
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Bridgewater, NJ (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
673021 CFR 314.80(b)Failure to develop written procedures